17 results about "Gonadotropin" patented technology

The invention provides a polypeptide with an ovary maturation promoting effect and application of the polypeptide in parturition induction of pomfret. The amino acid sequence of the polypeptide is SEQ ID NO: 1. The polypeptide provided by the invention is derived from the GnRH2 gene of the pomfret, and in-vivo experiments prove that the polypeptide can efficiently stimulate the pituitary of the pomfret to secrete gonadotropin, so that the spawning induction time is remarkably shortened, and the spawning rate and the relative spawning amount of parent fish are increased. The polypeptide is strong in species specificity and good in physiological compatibility, does not generate an antibody, avoids side effects of traditional heterologous hormones, is safe and effective, and has a huge potential of being developed into a special spawning induction agent for the pomfret.

The invention relates to the technical field of animal husbandry, in particular to a synchronous oestrus-timing insemination method suitable for cattle, which comprises the following steps: firstly, performing intramuscular injection of PG (cloprostenol sodium) at different time points after calving to promote uterine recovery and luteolysis and lay a synchronous oestrus foundation; the method comprises the key steps that GnRH (gonadotropin release hormone) is given through intramuscular injection on the 43rd day, the 53rd day, the 60th day and the 69th day, pituitary is promoted to release follicle-stimulating hormone (FSH) and luteinizing hormone (LH), collection and screening of follicles are guided, follicle maturation is promoted, the oestrus uncovering rate and the oestrus conception rate are increased, a melatonin implant is implanted in a subcutaneous implantation mode on the 63rd day, and the melatonin implant is implanted in a subcutaneous implantation mode on the 63rd day. The synthesis of ovarian hormones is promoted by regulating the hypothalamus-pituitary-gonad axis, the secretion of follicle cell factors and maturation promoting factors is promoted, the development of granular cells is promoted, and the maturation of oocytes is promoted. According to the method, the pregnancy rate of a double-synchronization-timing insemination scheme which is most widely used in a large-scale dairy cow breeding pasture at present can be remarkably increased, and feasible technical support is provided for success of increasing the breeding efficiency of cows.

The invention provides an individualized ovulation promoting scheme and gonadotropin initial dose prediction method based on multi-cycle time sequence modeling and related equipment, and is applied to the technical field of data processing. The method comprises the following steps: firstly, receiving multi-cycle clinical data and basic information of a target user for IVF / ICSI pregnancy-assisted patients, and eliminating unqualified samples to generate an initial data set; after SHAP screening features, training / test set division and SMOTE sample equalization are carried out, an initial model is constructed through a sliding window time sequence module and a multi-algorithm engine; a target model is generated through training and evaluation, and a COS scheme prediction signal and multi-period Gn dose adjustment information are generated in combination with hierarchical classification and weighted integration; calibration information is generated through clinical data verification, after target user information is subjected to standardization processing, an individualized COS scheme and a Gn initial dose are output through a target model, and multi-cycle dynamic accurate recommendation is achieved.

The invention provides an oral formulation and the method of preparation thereof for the delivery of a bioactive agent comprising a bioactive agent, a pH modifier, and a solid lipid matrix material, wherein the oral formulation is in the form of solid lipid microparticles formed from the solid lipid matrix material that encapsulates the bioactive agent and the pH modifier. In one embodiment, the bioactive agent is selected from one or more of glucagon-like peptide- 1 (GLP-1) analogues, luteinizing hormone-releasing hormone (LHRH) and gonadotropin-releasing hormone (GnRH), the pH modifier is a weak acid selected from one or more of phosphoric acid, citric acid, lactic acid and malic acid, and the solid lipid matrix material is selected from one or more of glyceryl behenate, glyceryl palmitostearate, tristearin, trimyristin, trilaurin, and stearic acid.

The present application relates to the field of biological products and veterinary medicine, and discloses a method for extracting and purifying blood gonadotropin, which comprises the following steps: 1) adjusting the pH of pregnant mare serum to 4.5-5.0 by using metaphosphoric acid, and performing solid-liquid separation to collect supernatant; 2) precipitating the supernatant by using a first precipitant, and collecting filtrate; 3) precipitating the filtrate by using a second precipitant, collecting precipitate, and drying the precipitate to obtain crude blood gonadotropin; 4) dissolving the crude blood gonadotropin, and sequentially performing first ultrafiltration, affinity chromatography, second ultrafiltration, and cation exchange chromatography to obtain crude blood gonadotropin filtrate; precipitating the crude blood gonadotropin filtrate by using a third precipitant, collecting precipitate, and drying the precipitate to obtain pure blood gonadotropin. The purity of the blood gonadotropin prepared by the extraction and purification method can reach more than 99.9%, the total yield can reach 88.9%, and the titer can reach 11000 IU / mg.

The invention discloses a composition for promoting gonad maturation of wild sal-family large yellow croakers and application of the composition, and belongs to the technical field of aquaculture. Through scientific proportioning of gonadotropin releasing hormone (GnRH) or analogues, polypeptide gonadotropin (FSH, LH) and auxiliary hormone (dopamine receptor antagonist), multi-target activation of an endocrine system of wild parent fish is realized, and synchronous maturation of gonads is promoted. Meanwhile, culture environment parameters such as illumination period, water temperature and salinity are optimized, an ecological environment suitable for sexual maturity is built, stress is reduced, the health of the parent fish is guaranteed, efficient, synchronous and safe sexual maturity of the parent fish is achieved, the breeding efficiency and the fry quality are remarkably improved, an artificial breeding technology of the Pseudosciaena crocea of the sal family is promoted to stride towards the scientization, standardization and industrialization direction, and the economic benefit is increased. And sustainable development of marine fishery resource protection and culture industry is promoted.

This invention relates to the treatment of breast cancer in a subject, and the subject can be either a male or female subject. Including methods of: treating metastatic breast cancer; refractory breast cancer; AR-positive breast cancer; AR-positive refractory breast cancer; AR-positive metastatic breast cancer; AR-positive and ER-positive breast cancer; triple negative breast cancer; advanced breast cancer; breast cancer that has failed selective estrogen receptor modulator (SERM) (tamoxifen, toremifene, raloxifene), gonadotropin-releasing hormone (GnRH) agonist (goserelin), aromatase inhibitor (AI) (letrozole, anastrozole, exemestane), cyclin-dependent kinase 4 / 6 (CDK 4 / 6) inhibitor (palbociclib (Ibrance), ribociclib (Kisqali), lerociclib, abemaciclib (Vorzenio), trilaciclib, lerociclib), mTOR inhibitor (everolimus), trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), alpelisib (Piqray) (an inhibitor of phosphatidylinositol-3-kinase subunit alpha (PI3Kα)), lapatinib, neratinib (Nerlynx), olaparib (Lynparza) (an inhibitor of the enzyme poly ADP ribose polymerase (PARP)), bevacizumab (Avastin), and / or fulvestrant treatments; metastasis in a subject suffering from breast cancer; HER2-positive; treating a subject suffering from ER mutant expressing breast cancer and / or treating breast cancer in a subject, by first determining the 18F-16β-fluoro-5α-dihydrotestosterone (18F-DHT) tumor uptake and identifying said subject as having AR-positive breast cancer based on 18F-DHT tumor uptake, comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound and a cyclin-dependent kinase 4 / 6 (CDK 4 / 6) inhibitor.

The utility model discloses a plasma separation device used in the haemotrophin production process, which comprises a supporting seat and a box body rotatably arranged at the top of the supporting seat, the top end of the box body is provided with an injection port, the top of the box body is provided with an installation cover, the top of the installation cover is rotatably connected with a rotating seat, the top of the rotating seat is integrally provided with a boss, and the boss is provided with an opening. A lifting sliding rod capable of being adjusted in a lifting mode is arranged in the boss, the bottom of the lifting sliding rod extends into the box body and is fixedly connected with a lifting base, a disc-shaped brush is installed at the bottom of the lifting base, an annular brush is installed on the outer side of the lifting base, and a brush of the annular brush makes contact with the inner wall of the box body. Due to the design of the lifting sliding rod and the lifting seat, the height of the cleaning brush can be adjusted according to needs, so that the cleaning brush can be better attached to the inner wall of the box body, all-dimensional cleaning without dead corners is achieved, through the combination of the disc-shaped brush and the annular brush, not only can the side wall of the box body be cleaned, but also the bottom of the box body can be particularly cleaned, and the sanitary state of equipment is ensured.

This invention belongs to the field of assisted reproductive technology, specifically relating to a controlled ovarian stimulation method and supporting drug composition for in vitro fertilization-embryo transfer. The core of this invention does not use GnRH agonists or antagonists throughout the entire process, employing clomiphene combined with individualized, adequate doses of postmenopausal gonadotropins to induce ovulation. A combined packaged drug composition of these two drugs is provided to suit the needs of individuals with high, normal, and low ovarian responses. This method achieves an early ovulation rate of less than 0.2%, an incidence of ovarian hyperstimulation syndrome of less than 1%, and reduces the cost of ovulation induction drugs per cycle by more than 80% compared to existing mainstream methods. It also boasts a stable clinical pregnancy rate and can be widely applied to assisted reproductive ovulation induction treatment for various infertile patients, significantly reducing their economic and time burden.

This invention relates to the field of aquaculture technology, specifically a feed formulation and preparation method for improving the reproductive performance of broodstock tiger prawns. The method includes: determining the specific nutritional requirements of broodstock tiger prawns during gonadal development; screening core animal and plant protein sources and determining their basic mass ratios accordingly; performing targeted biological treatment on the core raw materials to enrich gonadotropin-active small molecules; compounding these with phospholipids, attractants, vitamins, and minerals to form a functional additive combination; mixing the core raw materials and additive combination in proportion, granulating, and adding antioxidants during processing; and finally verifying the formulation effect and confirming the final compound feed through standardized aquaculture trials. The compound feed obtained based on this method can effectively replace traditional live feed, improve broodstock tiger spawning, hatching rate, and larval quality, and has advantages such as balanced nutrition, stable quality, and suitability for large-scale production, solving the industry problems of live feed being prone to pathogens, supply fluctuations, and high costs.

The application discloses a fermentation process of gonadotropin-releasing hormone hexamer-diphtheria toxin mutant CRM197, and the process comprises the following steps: screening of a fermentation medium and optimization of fermentation conditions. The fermentation medium comprises yeast extract powder, tryptone and NaCl, and the optimization of the fermentation process comprises culture temperature, an inducing agent, concentration of the inducing agent, culture time after induction, adjustment mode of pH of the fermentation liquor, stirring speed, ventilation amount and the like. The fermentation process has the advantages of low production cost, short production cycle (only 12-15 hours are needed), improved expression amount of the target protein per unit of bacteria, and realized high-efficiency expression of the target protein. The GnRH6-CRM197 prepared by the application can be used for immunocastration of various mammals, and has the values of further research and development and good industrialization prospect.

Described herein are radiotherapeutics that target tumor cells expressing the gonadotropin-releasing hormone receptor (GnRHR) and their use in the treatment and / or diagnosis of cancer.

The present application relates to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition and preparation and application thereof. The composition provided by the present application comprises Ramulus cinnamomi, Poria cocos, Cortex moutan, Semen persicae, Radix paeoniae alba, Radix rubiae, Cornus officinalis, and Rhizoma sparganii. The composition can obviously reduce the prostate index and prostate epithelial thickness of a benign prostatic hyperplasia model rat, and relieve interstitial edema. The experimental results show that the composition can obviously reduce the content of dihydrotestosterone, estradiol, testosterone, gonadotropin-releasing hormone, and rat luteinizing hormone in the prostate serum of a model mouse, and increase the content of follicle-stimulating hormone. The above results show that the traditional Chinese medicine composition can inhibit sex hormone disorder, and has the effect of treating prostatic hyperplasia.

The invention provides a method for regulating and inducing conception of non-pregnant non-oestrus dairy cows. The method is characterized by comprising the following steps: 1) detecting LH and FSH levels and performing staging; 2) carrying out regulation and targeted induction on cows with different LH and FSH stage levels; and 3) artificial insemination. Targeted treatment and precise regulation and control are achieved for high-difficulty breeding cases of 37 sky huai, no oestrus, lasting corpus luteum and uterus residues. The prostaglandin PGF2a + oxytocin + gonadotropin releasing hormone GnRH combined intramuscular injection scheme is adopted, lasting corpus luteum is thoroughly dissolved, residual embryonic tissues in the body are removed, the uterus is purified, the subsequent conception environment quality is remarkably improved, ultrasonic monitoring does not need to be frequently used, individualized and refined hormone regulation is achieved, the conception rate is remarkably increased, and meanwhile the conception time is shortened. The one-birth double-calf rate is stably improved, and the breeding economic benefits are greatly improved.

The application provides an INH-GNIH double expression gene vaccine containing improved animal reproductive capacity and an engineering strain thereof, which is preserved in the China Center for Type Culture Collection on August 15, 2018, and the preservation number is CCTCC NO: M 2018541. A preparation method of the INH-GNIH double expression gene vaccine is provided, and the engineering strain is directly immunized to animals or mixed with a DNA vaccine adjuvant before being immunized to animals, so that the reproductive capacity of the animals can be effectively improved. The double expression gene is a double expression non-resistance DNA plasmid of inhibin and gonadotropin-releasing inhibitory hormone, and the animals can be directly immunized through mucosal immunization by means of nose spraying, oral administration, feed mixing and the like to generate antibodies. Since the double expression gene does not contain a resistance gene, it is unnecessary to introduce an exogenous antibiotic for screening, so that no antibiotic residue is generated. Compared with other gene vaccines, the plasmid needs to be extracted and purified, the production cost is relatively high, the muscle injection is troublesome, and the animals generate a stress reaction. The vaccine has low production cost, is convenient to use, has no resistance and injection stress reaction.

The invention discloses a method for judging low, medium and high reaction of ovarian stimulation of dairy cows, which belongs to the field of ovarian stimulation judgment of dairy cows and comprises the following steps: selecting clinically healthy Holstein dairy cows as donors, and performing ovarian stimulation treatment on the donors; and carrying out living body ovum collection (OPU) on the donor subjected to ovary stimulation treatment, and recording the total number of sucked follicles, the total number of recovered oocytes and oocyte quality grading. The ovarian sensitivity index (OSI) system in the field of human assisted reproduction is applied to dairy cow ovarian stimulation response judgment for the first time, a judgment system with OSIbov as the core is established, and the defect that in the prior art, standardized and dynamic judgment indexes are lacked is overcome. The OSIbov highlights the conversion dynamic state and the gonadotropin sensitivity by quantifying the number of COCs obtained by each unit of exogenous FSH instead of only paying attention to the absolute number, the reaction difference of the cow ovary to stimulation can be accurately captured, and the misclassification problem caused by static indexes is avoided.

The invention provides oral oxytocic hormone feed for parent fish of wild sal-family pseudosciaena crocea as well as a preparation method and application of the oral oxytocic hormone feed, and belongs to the technical field of breeding of the wild sal-family pseudosciaena crocea. According to the oral oxytocin feed for the parent fish of the wild sal-family large yellow croaker, provided by the invention, a high-protein floating compound feed is taken as a carrier, and a gonadotropin releasing hormone analogue GnRH-a, a dopamine receptor antagonist DOM, vitamin E powder, immune polysaccharide for fish and seaweed meal are added. The invention further provides a preparation method and application of the oral oxytocic hormone feed for the parent fish of the wild sal-ammoniac pseudosciaena crocea, and provides an oxytocic, insemination and artificial propagation method for the wild sal-ammoniac pseudosciaena crocea, so that the propagation success rate and the fry quality of the wild sal-ammoniac pseudosciaena crocea are remarkably improved; the technical bottlenecks of stress sensitivity, asynchronous oviposition, unstable egg quality and the like of wild parent fish are overcome, and the method has remarkable popularization value and industrial application prospect.